Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation.
about
USP21 regulates Hippo pathway activity by mediating MARK protein turnover.Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma.+1q: amplifying the bad genes in myeloma.Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting
P2860
Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Gain of chromosome 1q portends ...... nd autologous transplantation.
@en
type
label
Gain of chromosome 1q portends ...... nd autologous transplantation.
@en
prefLabel
Gain of chromosome 1q portends ...... nd autologous transplantation.
@en
P2093
P2860
P1433
P1476
Gain of chromosome 1q portends ...... nd autologous transplantation.
@en
P2093
Alexander M Lesokhin
David J Chung
Dory Londono
Guenther Koehne
Gunjan L Shah
Hani Hassoun
Heather Landau
Nikoletta Lendvai
Ross Levine
Satyajit Kosuri
P2860
P304
P356
10.1080/10428194.2016.1260126
P50
P577
2017-01-12T00:00:00Z